PURIVAX (TM) Technology from GeneThera Can Facilitate Faster Development of Avian Flu Vaccine.WHEAT RIDGE, Colo. -- GeneThera (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :GTHA) announces that its Purivax(TM) technology -- a large-scale process for highly purified and high viral titer Adenovirus adenovirus Any of a group of spheroidal viruses, made up of DNA wrapped in a protein coat, that cause sore throat and fever in humans, hepatitis in dogs, and several diseases in fowl, mice, cattle, pigs, and monkeys. and AAV recombinant vectors, would enable fast track development of Adenovirus and AAV-based recombinant DNA vaccines for diseases such as the Avian Flu (commonly called Bird Flu). GeneThera's PURIVAX(TM), is a multi-resin anion exchange chromatography system that dramatically improves biological purity and viral titer of recombinant Adenovirus and AAV vectors. PURIVAX(TM), completely eliminates toxic side effects associated with adenoviruses and AAV vectors thereby making it possible to quickly develop highly immunogenic im·mu·no·gen·ic adj. Producing an immune response. immunogenic producing immunity; evoking an immune response. and safe recombinant DNA vaccines, which are significantly more efficacious in fighting today's bacterial and viral diseases like Bird Flu, as well as food pathogen applications. Importantly, recombinant DNA (rDNA) vaccine technology represents a powerful tool for an innovative vaccine design process known as "genetic immunization." Dr. Tony Milici, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of GeneThera remarked, "GeneThera's PURIVAX(TM) is able to achieve both high purity and high viral titer (up to 10e16 viral particles/eulate) based on its proprietary multi-resin anion exchange chromatography system, unlike traditional technologies and first generation chromatography processes that are inadequate, both in terms of purity and yield. The important significance to mankind is that our PURIVAX(TM) technology can help achieve accelerated development of an rDNA vaccine for veterinary diseases, such as the Bird Flu." ABOUT GENETHERA, INC.: GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease mad cow disease: see prion. mad cow disease or bovine spongiform encephalopathy (BSE) Fatal neurodegenerative disease of cattle. Symptoms include behavioral changes (e.g. , Chronic Wasting Disease Noun 1. chronic wasting disease - a wildlife disease (akin to bovine spongiform encephalitis) that affects deer and elk animal disease - a disease that typically does not affect human beings , a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johne's Disease, diseases affecting cattle worldwide. ``Safe Harbor'' Statement: Certain statements in this release are ``forward-looking'' statements as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence ob·so·les·cent adj. 1. Being in the process of passing out of use or usefulness; becoming obsolete. 2. Biology Gradually disappearing; imperfectly or only slightly developed. , competitive risks, reliance on development partners and the need for additional capital. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion